Docket No. JBP0438

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Miri Seiberg et al. Confirmation No.: 5255

Serial No.: 09/206,249 Art Unit: 1654

Filed: December 7, 1998 Examiner: Michael V. Meller

For : Compositions and Methods for Regulating

Phagocytosis and ICAM-1 Expression

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

March 25, 2005
(Date of Deposit)

Andrea L. Colby, Reg. No. 30,194 (Name of applicant, assignee, or Registered Representative)

/Andrea L. Colby/
(Signature)
March 25, 2005
(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on September 1, 2004.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this

information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☐ In accordance with §1.97(b), since this Information
Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application
(other than a continued prosecution application under
§1.53(d)), within three months of the date of entry into the
national stage of the above identified application as set forth
in §1.491, or before the mailing date of a first Office Action
on the merits of the above-identified application, or before
the mailing date of a first Office Action after the filing of a
request for continued examination under §1.114, no additional
fee is required.

☐ In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with ☐ the

In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with \Box the
First or 🗌 second After Final Submission, therefore:
<pre>Statement in Accordance with §1.97(e)</pre>
(attached); or
☐ Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in §1.17(p).

In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

Statement in Accordance with §1.97(e)
(attached); or
☐ Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in §1.17(p).
☐ In accordance with §1.97(d), this Information
Disclosure Statement is being filed after the mailing date of
either a Final Action under §1.113 or a Notice of Allowance
under §1.311 but before the payment of the Issue Fee.
Applicant(s) hereby petition(s) for consideration of this
Information Disclosure Statement. Included are: Statement in
Accordance with §1.97(e) as set forth below and the fee of
\$180.00 as set forth in §1.17(p).
☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
Copies of only foreign patent documents and non-
patent literature are enclosed in accordance with 37 CFR 1.98
(a)(2). (The U.S. patents and each U.S. patent application
publication listed on the attached Form PTO-1449 are not
enclosed because this U.S. patent application was filed after
June 30, 2003 or this international application has entered the
national stage under 35 USC §371 after June 30, 2003 (see USPTO
waiver of requirement under 37 CFR 1.98 (a)(2)(i).
$oxed{\boxtimes}$ There are no listed references which are not in the
English language.
The relevance of those listed references which are
not in the English language is as follows: .

☐ Att	tached are copies	of search	report(s) from	
corresponding	g patent applicat	ion(s), which	ch are listed on	the
attached Subm	mission Under MPE	P _. 609 D.		
☐ Att	tached are the fo	llowing non	-published pendir	ıg
patent applic	cations which may	be deemed	relevant, which a	ıre
listed on the	e attached Submis	sion Under N	MPEP 609 D.	
· ·				

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JBP0438/ALC. This form is submitted in triplicate.

Respectfully submitted,

/Andrea L. Colby/ Andrea L. Colby Reg. No. 30,194 Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2793
DATED: March 25, 2005

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required
Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 1

to respond to a collection of information unless it displays a valid OMB control number.				
Confirmation Number	5255			
Application Number	09/206,249			
Filing Date	12/07/1998			
First Named Inventor	Miri Seiberg			
Group Art Unit	1654			
Examiner Name	Michael V. Meller			
Attorney Docket Number	JBP438			

		U.S. Pa	tent Docume	ent					
Exam Initials	Cite No.1	i i	Kind Code ² er (if known)			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages of relevant figures appear	
		4,603	3,146		Α	Kligman	07-29-1986		
		4,727	7,088		Α	Scott et al.	02-23-1988		
		5,670	0,547	-	Α	Milstein et al MAR 2 8 2005	09-23-1997		
						TRADEMANDE TRADEMAND			
						PRADEMAN			
			-				·		
						FOREIGN PATENT DOCUMENTS			
		Foreign Patent Document				Date of Publication of	Pages, Columns, Lines, where relevant		
Exam Initials	Cite No. ¹	Office ³	Number ⁴	KindCo	de ⁵	Name of Patentee or Applicant of Cited Document	Cited Document mm-dd-yyyy	passages or relevant figures appear	T ⁶
		-							<u> </u>
									ļ
									<u> </u>
					1				

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²

OTHER DRIOR ART. MON BATENT LITERATURE DOCUMENTS

	·		
Examiner		Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.